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DObjective: To compare early and late outcome of patients with prosthetic valve endocarditis treated medically
versus surgically and to determine predictors of in-hospital death. We retrospectively reviewed patient’s clinical
records, including laboratory findings, surgery, and pathologic files, in an acute-care, 1200-bed teaching hospital.
Methods: One hundred thirty-three episodes of definite prosthetic valve endocarditis as defined by the Duke
University diagnostic criteria occurred in 122 patients from January 1986 to December 2005. Logistic regression
model was used to identify prognostic factors of in-hospital mortality. Long-term follow-up was made to assess
late prognosis.
Results: Bioprostheses were involved in 52% of cases and mechanical valves in 48%. The aortic valve was
affected in 45% of patients. Staphylococcus epidermidis was isolated in 23% of cases, Streptococcus spp in
21%, S aureus in 13%, and Enterococcus in 8%. Cultures were negative in 18% of cases. Twenty-six patients
were treated medically and 107 with combined antibiotics and valve replacement. The operative mortality was
6.5% and the in-hospital mortality, 29%. Presence of an abscess at echocardiography, urgent surgical treatment,
heart failure, thrombocytopenia, and renal failure were significant predictors of in-hospital death. Kaplan-Meier
survival at 12 months was 42% in patients treated medically and 71% in those treated surgically (P ¼ .0007).
Freedom from endocarditis was 91% at the end of follow-up.
Conclusions: Prosthetic valve endocarditis is a serious condition with high mortality. Patients with perivalvular
abscess had a worse prognosis, and combined surgical and medical treatment could be the preferred approach to
improve outcome. (J Thorac Cardiovasc Surg 2010;139:887-93)Prosthetic valve endocarditis (PVE) is a rare but severe
complication of valve replacement and has been reported
to occur with an incidence of 0.98 per 100 patient-years.1
The cumulative incidence at 5 years is 3% and at 10 years
is 5%,2 with a case-mortality rate ranging from 25% to
59%,3 despite improvements in prophylaxis, diagnosis,
and treatment. The best therapeutic option in PVE is still
debated. Although surgical therapy is said to represent the
best choice,4,5 medical therapy can be sufficient in some
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The Journal of Thoracic and CaThe objective of this study was to describe the clinical
features of patients with PVE, to determine predictors of
in-hospital death, and to compare early and late outcome
of patients with PVE treated medically versus surgically.PATIENTS AND METHODS
The study was conducted at an acute-care, 1200-bed teaching hospital.
The hospital has a department of cardiovascular surgery, a cardiology
service, and a unit of infectious diseases and has been a reference center
of cardiovascular surgery for other hospitals in the country. From January
1986 to December 2005, a total of 133 consecutive episodes of definite
PVE as defined by Duke University diagnostic criteria7 were treated at
our institution. A retrospective review of the patient’s clinical records, in-
cluding laboratory findings, surgery, and pathologic files, forms the basis
of the present report. The primary end points of the study were in-hospital
death and survival at 12 months after combined medical and surgical
treatment versus medical therapy alone. The study was approved by the
Institutional Review Board.
Early PVE was defined as the diagnosis of PVE within 60 days of
prosthetic valve implantation, and late-onset was defined as PVE occurring
2 or more months after valve replacement.8 All patients were scheduled for
4- to 8-week antibiotic therapy. All operations were performed at the depart-
ment of cardiovascular surgery of our hospital. Urgent surgery was defined
as valvular replacement performed within 24 hours after hospital admission.
Indications of surgery and the choice of the best valvular substitute were left
to the discretion of the attending physician. Intraoperative decisions and the
treatment protocols for these patients varied over the study period. Briefly, if
the indication of surgical treatment was an urgent operation (<24 hours after
admission), the infected prosthesis was substituted by a new one accordingrdiovascular Surgery c Volume 139, Number 4 887
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CI ¼ confidence interval
NYHA ¼ New York Heart Association
PVE ¼ prosthetic valve endocarditis
RR ¼ risk ratioto criteria of the responsible surgeon, but in most cases the same model
of prosthetic valve was used. The same occurred for endocarditis on
a prosthetic mitral valve, except for a patient with recurrent mitral valve
endocarditis in whom a mitral homograft was implanted. In patients with
prosthetic endocarditis of the aortic valve in which surgery could be delayed
24 to 48 hours, a cryopreserved aortic root homograft from a tissue bank
was inserted.
Medical records of patients were reviewed for data on age, sex, place of
origin (our community or reference from other communities), preoperative
functional class according to the New York Heart Association (NYHA)
classification, previous endocarditis with native or prosthetic valves, and de-
tails of previous valve surgery, including intraoperative and perioperative
data. The presence of congestive heart failure was based on characteristic
signs and symptoms determined by clinicians at the individual sites. Neuro-
logic abnormalities were defined as clinical signs of cortical and subcortical
lesions (eg, hemiparesis, aphasia), brain stem lesion, meningitis, or altered
consciousness. Abnormal laboratory findings included serum creatinine
concentration>133 mmol/L, white blood cell count<3 3 109/L or>16
3 109/L, and sedimentation rate>40 mm/h. Complicated PVE was defined
as the presence of a new or changing heart murmur, new or worsening heart
failure, new or progressive cardiac conduction abnormalities, prolonged
fever during therapy, or intracardiac abscess by echocardiography or the
presence of pus by direct visualization at surgery or necropsy.9 Uncontrolled
infection was defined by persistent fever or persistent bacteremia or both
after 1 week of appropriate antimicrobial chemotherapy.10 Septic shock
was defined as a persistent hypotension (systemic blood pressure  90
mm Hg) not due to cardiogenic shock and along with the presence of at least
one of the following signs of perfusion abnormalities: oliguria, acute alter-
ation of mental status, or lactic acidosis.11 Relapse was defined as a fresh
onset of clinical endocarditis with blood cultures positive for the initial path-
ogen within 12 months after hospital discharge. Reinfection was defined as a
subsequent episode in which a different pathogen was isolated. The routine
microbiologic screening also included fastidious organisms, anaerobes,
fungi, and organisms from the HACEK group. Etiologic microorganism
was defined as microorganism grown from blood or tissue culture sources
determined to be the causative agent for the PVE episode.12 Otherwise,
the diagnosis of culture-negative PVE was established. In-hospital mortality
was defined as death occurring during the initial hospitalization for infective
endocarditis.
Transthoracic and/or transesophageal echocardiography as clinically
indicated was performed. Vegetations were defined as circumscribed
masses or clumps of echoes that arose from leaflet tips or prosthetic material,
either as an irregular area of highly reflective leaflet thickening or as more
discrete, pedunculated masses. Nonspecific valvular thickening was not
interpreted as vegetations. An abscess was considered in the presence of
abnormal echo-dense or echo-lucent areas within the valvular annulus or
perivalvular tissue, confirmed by imaging in more than 1 echocardiographic
plane, in the setting of valvular infection.13
The follow-up data for this study were procured in a 1-month period
(June 2006). The patients were followed through visits in the outpatient
clinic, direct telephone contact at home, or direct contact with their
physicians. When follow-up was not possible, information on vital status
(alive or death) and cause of death was obtained through the Social Security
database.8 The Journal of Thoracic and Cardiovascular SurgStatistical Analysis
A logistic regression model was used to evaluate the effect of explana-
tory variables on in-hospital mortality. In both the univariate and multi-
variable analysis, continuous variables were categorized using the most
clinically relevant cutoff points. Variables were entered into a stepwise
backward multiple logistic regression model. Results are expressed as crude
and adjusted odds ratios with 95% confidence intervals (CIs). All factors
were adjusted by sex, age, year of diagnosis of PVE, referral hospital, and
nosocomial infection after original valve replacement. Survival analysis
was used to compare event rates during the follow-up period with compar-
isons made with the Kaplan-Meier method. Mortality rates for PVE were
evaluated by plotting the survival distribution derived from Kaplan-Meier
estimates, and differences in survival were assessed by the log-rank test.
A Cox regression analysis was performed to assess the effect of the different
variables on the risk of death. The risk ratio (RR) and the 95% CI were cal-
culated. Data were analyzed using Stata statistical software (Release 8.0,
Stata Corporation, College Station, Tex) and SPSS (version 11.5; SPSS
Inc, Chicago, Ill).RESULTS
A total of 133 episodes of PVE were diagnosed (112
patients had 1 episode, 9 patients had 2 episodes, and 1
patient had 3 episodes). There were 87 men and 34 women
with a mean age of 59 years (95% CI: 56–62). During the
same period, 6079 valve replacement operations were per-
formed, with an incidence of PVE of 2.2%. Sixty-nine epi-
sodes occurred in patients who had bioprosthetic valve
replacement and the remaining 64 in patients who had
mechanical valve replacement. Location of infected prosthe-
sis included aortic in 60 cases, mitral in 37, and mitroaortic
in 36. Laboratory findings showed leukocytosis or leukope-
nia in 60% of the episodes, sedimentation rate>40 mm/h in
24%, and serum hemoglobin<10 g/dL in 8%. Echocardi-
ography revealed vegetations in 63.1% of cases, prosthetic
valve dysfunction in 71.4%, abscess in 39.3%, and aorto-
ventricular dehiscence in 9.7%.
Of the 133 cases of PVE, there were 24 cases (18%) of
early onset PVE and 109 (82%) of late-onset PVE. Mechan-
ical PVE was more frequent in the early onset PVE group
(78% vs 22%), whereas bioprosthetic PVE was more fre-
quent in the late-onset group (58% vs 42%). Coagulase-
negative staphylococci were observed most often in both
early PVE (47%) and late PVE (29%) groups. Staphylococ-
cus aureus was the second most frequent organism in early
PVE (25%) and Streptococcus viridans in late PVE (19%).
The percentage of methicillin-resistant S aureus was higher
in early PVE (40%, 10/25) than in late PVE (23%, 3/13).
Cultures were negative in 24 cases (18%). Complications
during hospitalization occurred in 96 of the 133 episodes
of PVE (72.2%), with a rate of 66.7% (16/24) in early
PVE and 73.4% (80/109) in late PVE. Clinical features, mi-
crobiologic data, and complications in all episodes of PVE
as well as in the groups of early and late PVE are shown
in Table 1.
Thirty-nine patients died, for an in-hospital mortality rate
of 29.3%. Causes of death included heart failure orery c April 2010
TABLE 1. Clinical characteristics,microbiologicdata, andcomplications
in 133 episodes of PVE
All episodes Early PVE Late PVE
No. cases 133 24 109
Clinical features
Fever 106 (79.7) 17 (70.8) 89 (84.0)
Heart failure 87 (65.4) 18 (75) 69 (63.3)
Systemic embolism 6 (4.5) 1 (4.2) 5 (4.6)
Splenomegaly 15 (11.3) 1 (4.2) 14 (12.8)
Osler nodes,
Janeway lesions
7 (4.3) 1 (4.2) 4 (3.7)
New or changing
murmur
85 (63.9) 13 (54.2) 72 (66.1)
Causative
microorganisms
109 (81.9) 21 (87.5) 88 (80.7)
Coagulase-negative
Staphylococci
36 (27.1) 9 (37.5) 27 (24.8)
Staphylococcus
aureus
17 (12.8) 5 (20.8) 12 (11.0)
Methicillin-
sensitive S aureus
12 (9.0) 3 (12.5) 9 (8.2)
Methicillin-resistant
S aureus
5 (3.7) 2 (8.3) 3 (2.7)
Streptococcus
viridans
21 (15.8) 1 (4.2) 20 (15.1)
Enterococcus 9 (6.8) 1 (4.2) 8 (7.3)
Diphtheroids 1 (0.7) 1 (4.2) 0
Gram-negative
bacilli
4 (3.0) 0 4 (3.7)
Peptococcus spp 1 (0.7) 0 1 (0.9)
Candida spp 4 (3.0) 0 4 (3.7)
Miscellaneous 16 (12.0) 4 (16.7) 12 (11.0)
Negative culture 24 (18.0) 3 (12.5) 21 (19.3)
Complications during
hospitalization
96 (72.2) 16 (66.7) 80 (73.4)
Respiratory failure 23 (17.3) 5 (20.8) 18 (16.5)
Severe heart failure 42 (31.6) 7 (29.2) 35 (32.1)
Renal failure 47 (35.3) 9 (37.5) 38 (34.9)
Third-degree
atrioventricular block
13 (9.8) 2 (8.3) 11 (10.1)
Neurologic events 18 (13.5) 3 (12.5) 15 (13.8)
Uncontrolled infection 19 (14.3) 4 (16.7) 15 (13.8)
Septic shock 13 (9.8) 4 (16.7) 9 (8.2)
Data as absolute numbers and percentages in parenthesis. PVE, Prosthetic valve
endocarditis.
TABLE 2. Results of univariate analyses: Risk factors for in-hospital
death in 133 episodes of PVE
Crude mortality
RR 95% CI P value
Age>75 y 1.6 0.6–4.3 NS
Year of PVE diagnosis 1986–
1995
0.9 0.4–1.9 NS
Female gender 1.2 0.6–2.7 NS
Previous infective
endocarditis
1.7 0.7–4.4 NS
Previous valve replacement 0.9 0.4–2.1 NS
Comorbidity 2.4 0.1–40.1 NS
Mechanical prosthesis
implantation
1.1 0.5–2.4 NS
Involvement of the aortic
valve
1.7 0.7–3.64 NS
Early PVE 1.9 0.8–4.92 NS
Onset<3 mo of index
operation
2.3 1.1–5.4 .044
Fever 2.0 0.7–5.9 NS
New or changing murmur 1.2 0.5–2.6 NS
Systemic emboli 2. 3 0.4–12.1 NS
White blood cell count<3 3
109/L or>16 3 109/L
2.8 1.1–6.9 .023
Positive blood cultures 1.0 0.3–2.7 NS
Staphylococcus aureus
infection
2.1 0.7–2.0 NS
Vegetation in the
echocardiogram
1.5 0.6–3.2 NS
Abscess in the
echocardiogram
3.5 1.6–7.8 .0016
Prosthesis regurgitation 0.9 0.4–1.9 NS
New valve dehiscence 2.2 0.7–7.2 NS
Left ventricular ejection
fraction<30%
17.0 1.4–210 .0082
Surgical treatment 0.5 0.2–1.2 NS
Urgent surgery 3.9 1.5–9.8 .0035
Abscess detected at surgery 2.7 1.1–6.5 .024
Respiratory failure 4.2 1.6–10.7 .0017
Renal failure 2.2 1.03–4.8 .038
Heart failure 9.7 4.1–22.9 .00001
Thrombocytopenia 4.5 1.0–19.6 .034
Third-degree atrioventricular
block
1.6 0.5–5.1 NS
Neurologic events 2.2 0.8–5.9 NS
Complicated PVE 1.7 0.7–4.2 NS
Uncontrolled infection 14 4.3–46.2 .00001
Severe sepsis 10 1.9–50.9 .0009
Septic shock 41 5.1–332.3 .00001
PVE, Prosthetic valve endocarditis; RR, risk ratio; CI, confidence interval.
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uncontrolled infection in 8, and other in 9. A total of 107
patients had surgical valve replacement during the acute
phase of the disease. Urgent surgery was necessary in 51
cases (38.3%).
In the univariate analysis (Table 2), factors significantly
associated with in-hospital death were onset of PVE within
the first 3 months after the index valve replacement opera-
tion, leukopenia or leukocytosis, presence of an abscess
detected by echocardiography or at surgery, left ventricular
ejection fraction<30%, urgent surgery, respiratory failure,The Journal of Thoracic and Carenal failure, heart failure, thrombocytopenia, uncontrolled
infection, severe sepsis, and septic shock. All these factors
except thrombocytopenia were significant predictors of in-
hospital mortality in the multivariate analysis (Table 3). In
addition, the presence of third-degree atrioventricular blockrdiovascular Surgery c Volume 139, Number 4 889
TABLE 3. Results of multivariate analyses: Risk factors for
in-hospital death in 133 episodes of PVE
Adjusted mortality
OR* 95% CI P value
Onset<3 mo of index
operation
7.0 1.02–47 .047
White blood cell count<3 3
109/L or>16 3 109/L
4.8 1.5–15.4 .009
Abscess in the
echocardiogram
3.2 1.3–7.8 .01
Urgent surgery 3.9 1.5–9.9 .02
Abscess detected
at surgery
3.9 1.2–9.4 .019
Respiratory failure 4.5 1.5–13.2 .006
Renal failure 2.9 1.2–7.1 .018
Heart failure 11 4.3–39.8 .0001
Third-degree
atrioventricular block
3.7 1.15–12 .028
Complicated PVE 2.6 0.8–7.8 .085
Uncontrolled infection 17 4.4–65.7 .0001
Severe sepsis 11 1.8–61.3 .008
Septic shock 42 4.9–356.8 .001
PVE, Prosthetic valve endocarditis; OR, odds ratio; CI, confidence interval. *All fac-
tors adjusted by: sex, age, year of PVE onset, referral hospital, nosocomial infection
after original valve replacement.
TABLE 4. Demographic and clinical features between the surgically
treated and nonsurgically treated groups of PVE
Surgical, n (%)
(n ¼ 107)
Medical therapy
only, n (%)
(n ¼ 26) P value
Age, years, mean (SD) 57 (15) 66 (14) .01
Male patients 75 (70.1) 15 (57.7) .25
Diabetes mellitus 6 (5.6) 4 (15.4) .11
Renal failure 1 (0.9) 1 (3.8) .35
Neoplasms 3 (2.8) 2 (7.7) .25
Intravenous drug users 2 (1.9) 0 .65
Immunosuppression 3 (2.8) 0 .52
Severe comorbidity 2 (1.9) 0 .65
Early PVE 17 (15.9) 7 (26.9) .25
Fever 82 (76.6) 24 (92.3) .10
NYHA functional
class IV
40 (37.4) 4 (15.4) .36
Staphylococcus aureus
infection
14 (13.1) 4 (15.4) .75
Complicated PVE 83 (77.6) 13 (50) .007
Severe sepsis 4 (3.7) 5 (19.2) .14
PVE, Prosthetic valve endocarditis; SD, standard deviation; NYHA, New York Heart
Association.
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nificant predictors in the logistic regression model.
In 26 episodes of PVE occurring in 25 patients, medical
treatment only was indicated. One patient with 2 episodes
of PVE received only medical treatment because prosthetic
valve dysfunction was not observed. In the remaining 24
patients, surgical treatment was not performed for the fol-
lowing reasons: absence of prosthetic valve dysfunction in
10, severe sepsis in 5, cerebral embolism in 3, cardiogenic
shock in 2, acute renal failure in 1, and unknown cause in
3. As shown in Table 4, demographic and clinical features
of surgically treated and nonsurgically treated patients
were similar, although medically treated patients were sig-
nificantly younger and a significantly lower percentage of
patients had complicated PVE as compared with the surgical
group. Moreover, more patients in the surgical group were in
NYHA functional class IV. The in-hospital mortality rate
was 26% in the medical-surgical group versus 42% in the
medical therapy alone group (P ¼ NS).
Recurrent PVE was observed in only 12 cases (9%):
a recurrent episode of valve infection was detected in 10
episodes and a relapse in 2. Fifty percent of patients were
carriers of mechanical valve prosthesis, and 50% of biologic
prosthesis (patients with multiple valve replacement in 60%
of cases). Only 1 case had a positive culture in which
Candida albicans was recovered.
The mean length of follow-up was 32.2 months (standard
deviation 46.8, range 0–212 months). Freedom from endo-
carditis was 91% at the end of follow-up. Cumulative sur-890 The Journal of Thoracic and Cardiovascular Surgvival was 68% at 3 months, 64% at 6 months, and 63%
at 12 months. Among the 94 patients who were discharged
alive from the hospital, 26 (27%) died during a mean
follow-up period of 31 months. As shown in Figure 1, 12-
month survival was 71% in the medical-surgical group com-
pared with 42% in the medical group (log-rank test 11.48,
P ¼ .0007). In the Cox regression analysis, surgical treat-
ment was a significant predictor of survival (RR ¼ 0.43,
95% CI 0.24–0.75, P ¼ 0.003). Differences in survival
regarding early and late PVE and study period (1986–
1995 vs 1996–2005) were not observed.DISCUSSION
Infection of intracardiac prostheses is a serious, often life-
threatening complication of valve replacement surgery14 de-
spite prompt diagnosis, antibiotic therapy, and the frequent
indication of replacement of the infected valve. The present
study carried out in a large population of patients with PVE
also documents the high morbidity and mortality of this
condition.
One major problem when assessing the prognosis of PVE
is that previous studies have included a spectrum of hetero-
geneous patients in whom the diagnosis of PVE was not
proven. In the study of Kuyvenhoven and colleagues,3
proven PVE was only documented in 39 of 70 episodes,
whereas in the study of Yu and associates,15 definite endo-
carditis was diagnosed in 42 of 74 patients. To allow valid
interpretation of the data in our study, we included only pa-
tients with definite diagnosis of PVE according to Duke
criteria.7 In our population of patients with definite PVEery c April 2010
FIGURE 1. Long-term survival of patients with prosthetic valve endocar-
ditis after combined medical and surgical treatment (upper line) or medical
treatment alone (lower line).
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other major criteria of endocarditis were excluded, 18% of
cases of PVE occurred within the first 60 days after valve
replacement. This percentage is slightly lower than that
reported in previous studies, in which about one-third of pa-
tients had early onset PVE and two-thirds had late-onset
PVE.16 Although our study showed a higher mortality in pa-
tients with early PVE (42%) compared with those with late
PVE (26%), there were no statistically significant differ-
ences, which is in contrast with other studies.6,10
Due to the complexity of PVE, different clinical findings
on admission and late complications may influence the out-
come. Several studies have suggested that aortic prosthe-
ses17 and infection of a mechanical valve16 rather than
a porcine valve are associated with a higher mortality, but
other studies and our data showed no differences with regard
to these variables. Leukocytosis or leukopenia on admission
was the only variable significantly associated with in-hospi-
tal death. Although some studies have shown an association
between abnormal white blood cell count and mortality in
infective endocarditis,6 as far as we are aware, this is the first
study showing that this marker is an independent predictor
of mortality in the setting of PVE.
According to microbiology, early PVE is caused by con-
tamination of the artificial valve at the time of implantation
or by perioperative bacteremia, so that the most frequently
encountered pathogens in early PVE are coagulase-negative
staphylococci, followed by S aureus and Enterococcus.18
On the other hand, late PVE can be caused by different mi-
croorganisms.19 In agreement with other studies, we found
that coagulase-negative Staphylococcus was the most com-
mon causative microorganism for PVE, although recent
studies showed an increase in PVE caused by S aureus.14The Journal of Thoracic and CaA significant association between S aureus infection and
mortality in PVE has been reported. In our study, a trend to-
ward a higher mortality with staphylococcal infection was
noted, but statistical significance in the multivariate analysis
was not reached.
Echocardiographic findings have an important role in the
diagnosis and management of PVE.20 Echocardiographic
signs include vegetations on and around the prosthetic valve,
valve dysfunction (stenosis, regurgitation, perivalvular leak),
and invasion of perivalvular tissue by abscesses and fistulae.
Previous studies showed the association of periannular
complications in endocarditis in the setting of prosthetic valve
infection.20 However, the role of echocardiography in predict-
ing outcome has been poorly assessed. In the study of Habib
and associates,5 the presence of annular abscess was not asso-
ciated with increased mortality. In our study, we observed
a 29% rate of echocardiographic abscess in PVE patients,
which is higher than the results obtained in other studies,
which ranged from 12% to 19%.6,12,21 The mortality of these
patients was statistically significant in multivariate analysis.
In a recent prospective multicenter study, abscess formation
was included among the strongest predictors of mortality.12
We also observed a worse prognosis in patients with a low
ejection fraction. There are few comparable data in the litera-
ture concerning the ejection fraction as a predictor of outcome
in patients with PVE.22
The optimal treatment in PVE is still debated, but surgery
has become a mainstay in complicated PVE.14,17,23 The high
rate of subsequent valve failure in patients treated medically
is an argument in favor of surgical treatment. However, the
use and timing of surgery in an individual patient with PVE
is often a difficult and complex clinical decision. Calder-
wood and colleagues9 showed that patients not treated surgi-
cally during their initial hospital admission are at high risk of
progressive prosthesis dysfunction and require careful fol-
low-up. In contrast, early valve surgery appears to improve
the prognosis of PVE. The superiority of surgical treatment
compared with antibiotic treatment alone has been demon-
strated in several studies, so that an aggressive medical-sur-
gical approach is recommended.9,15 In our study population,
the surgery rate was relatively high when compare with data
from the literature. The main cause was that about 65% of
our patients were referred from other hospitals because of
associated morbidity and a complicated clinical course
of PVE. When we analyzed the outcome of patients accord-
ing to the treatment received, in-hospital mortality was lower
in the surgical group than in the medical group (26% vs
42%), although the differences were not statistically signif-
icant. Survival after 12 months of treatment, however, was
markedly different in favor of surgically treated patients
(71% vs 42%). Moreover, surgical treatment was an inde-
pendent significant variable associated with favorable out-
come in the Cox regression analysis (RR ¼ 0.43, P ¼
.003). Other studies have also assessed the benefits ofrdiovascular Surgery c Volume 139, Number 4 891
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pact of long-term survival.5,6 In the study of Wang and asso-
ciates,12 a trend toward a benefit of surgical treatment was
also reported. However, further studies are needed to define
more clearly the role, timing, and effect of surgery in PVE.
Chronic heart failure is the most common cause of death
in patients with PVE5,9 and also the most frequent indication
of surgical treatment in complicated infective endocarditis.
Heart failure in PVE results predominantly as a consequence
of valve destruction and secondary severe regurgitation
leading to pulmonary edema. In our study, like others,10
heart failure was one of the strongest predictors of in-hospi-
tal mortality. Uncontrolled infection, severe sepsis, and sep-
tic shock were predictors of death in the multivariate
analysis, reflecting the importance of sepsis in the outcome
of these patients. In addition, neurologic complications
were related to an adverse outcome, as previous studies
have pointed out.12,24 On the other hand, and in contrast to
other studies,9,10 a relationship between complicated PVE
and mortality was not observed.
After hospital discharge, the highest mortality rate was
observed during the first 3 months. After this period, the sur-
vival of the patients remain stable and freedom from endo-
carditis was 92% at the end of the follow-up period. The
differences between medical and surgical treatment in
long-term outcome are similar to previous studies5,15 and
add evidence of the importance of combined surgical and
medical treatment as the better treatment option in these pa-
tients. In fact, surgery was a significant protective factor for
survival in the Cox regression analysis. In our patients, the
medically treated group showed a higher in-hospital mortal-
ity rate than the surgically treated group, although differ-
ences were not significant. Although patients in the
medical therapy only group were older, a significantly lower
percentage was in NYHA functional class IV and had com-
plicated bacterial endocarditis compared with the surgical
group. Comorbidities in both groups were similar. Selection
of surgical treatment should be considered in an early phase
of the diagnosis of PVE and probably by a multidisciplinary
team (cardiologists, specialists in infectious diseases, cardio-
vascular surgeons). The decision of operation should not be
delayed as surgical mortality is related to the amount of an-
atomic damage, and it is well known that anatomic destruc-
tion reflects both aggressiveness of the causative pathogen
and duration of the disease.
Our study has several shortcomings. First, a prospective
randomized controlled trial remains the best way to evaluate
the effectiveness of different strategies in the management of
PVE but such a trial would take several years to recruit a suf-
ficient number of patients from a single center or may have
to involve multiple centers, leading to a nonhomogeneous
group of patients and management protocols. Thus, a retro-
spective review is a reasonable approach for attempting to
assess predictors of outcome in patients with PVE, although892 The Journal of Thoracic and Cardiovascular Surgretrospective studies are clearly hampered by lack of ran-
domization and therefore bias in the selection of treatment
methods. However, our surgical team had no significant dif-
ferences concerning intraoperative management, and there
was a formal policy in our hospital during the study period.
Second, our study was performed in a referral center; this
may introduce a referral bias in the result obtained, which
we tried to solve by introducing this variable in the multivar-
iate analysis. Third, survivor treatment selection bias could
be detected,25 although there were no significant differences
according to comorbidities or clinical situation between
medical or surgical patients treated, and a significant number
of patients in our study underwent urgent surgery. On the
other hand, only patients who fulfilled the Dukes criteria
for definite endocarditis were analyzed, which is in contrast
to previous studies in which such a strict criterion was not
used. Thus, our study is one of the largest single-center se-
ries published in the literature, and the present results may
contribute to a better knowledge of the clinical course and
outcome of this important disease.
In summary, the present findings, which should be inter-
preted considering the retrospective nature of the study, con-
firm that PVE is a serious condition with a high mortality.
Patients with perivalvular abscess had a worse prognosis,
and combined surgical and medical treatment could be the
preferred approach to improve outcome.
We thank Marta Pulido, MD, for editing the manuscript and for
editorial assistance. No external industry funding was received for
the study itself or for editorial assistance.References
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